Status:
COMPLETED
Survey on PD Patients With Depressive Symptoms
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
20+ years
Brief Summary
The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \*\*PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.
- Exclusion criteria:
- PD patients with the past history of suicidal attempt, suicidal ideation or tendency
- PD patients with suicidal ideation
- PD patients with the past history of suicidal tendency
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1089 Patients enrolled
Trial Details
Trial ID
NCT00614575
Start Date
January 1 2007
Last Update
August 6 2014
Active Locations (238)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Akashi, Japan
2
Boehringer Ingelheim Investigational Site 1
Akita, Japan
3
Boehringer Ingelheim Investigational Site 2
Akita, Japan
4
Boehringer Ingelheim Investigational Site
Asahikawa, Japan